Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07710196 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

Study acronym: SLORP Preserve
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 32 days later Feb 2029 → Apr 2029
See other at-risk trials from Nacuity Pharmaceuticals, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Start date: Aug 2026 to Oct 2026
    • Primary and study completion pushed from Feb 2029 to Apr 2029
    • Study sites: 0 to 1
    • Eligibility criteria expanded, about 26 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are: Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision. Participants will: Take NPI-001 or a placebo twice a day, every day for 24 months and visit the clinic 9 times for checkups and tests.
Trial Details
NCT Number NCT07710196
Lead Sponsor Nacuity Pharmaceuticals, Inc.
Collaborators: Foundation Fighting Blindness
Conditions
(from sponsor)		 Retinitis Pigmentosa (RP), Usher Syndrome
Related terms Retinitis Pigmentosa, Usher Syndromes
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov